Investor Presentation First Nine Months of 2023
102
Investor presentation
First nine months of 2023
Novo Nordisk is supporting use of non-invasive tests for MASH
diagnosis
Development and adoption of non-invasive tests (NITS)
Liver biopsy
NITS
Guidelines: NITs represented in guidelines
Practitioners: ~80% of HCPs perform MASH diagnostics with use of
various NITs, while biopsies are seldomly used
NIT development: Several available NITs in clinical practice. ELF test is
first prognostic tool to be granted FDA De Novo marketing
authorisation
Pharma companies: Embedding validation of NITs in clinical trials
NN Development
External
Real world
Novo Nordisk activities supporting non-invasive tests
in MASH diagnosis
Linking biomarkers and liver histology to outcomes
Disease understanding
Consortia
Collaborations with academia and other healthcare companies
Phase 2 trial with FGF21
Phase 3 ESSENCE trial (part 1 and 2), incl. screening data
19
Validate
diagnostic tests
Validate
tests for monitoring
Validate tests
for prognosis
Note: FDA De Novo provides a marketing pathway to classify novel medical devices for which general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, but for which there is no legally
marketed predicate device.
NITS: Non-invasive tests; MASH: Metabolic dysfunction-associated steatohepatitis; HCPs: Healthcare professionals; FDA: the US Food and Drug Agency; NN: Novo Nordisk; ELF: Enhanced liver fibrosis
Novo NordiskⓇView entire presentation